AI Summary & Key Takeaways
AI InsightAt the end of the study period the improvement on bone density was found to be statistically significant, however no statistically significant change was observed among the drugs used.
📌 3 Key Takeaways
Abstract
Aim: We evaluated the changes of bone mineral density (BMD) in osteoporotic patients, followed in Geriatric outpatient clinic of Cerrahpaşa Medical Faculty, Internal Medicine Department, who were using antiresorptif therapy. Material-Method: 142 patients, whose two DEXA measurements were performed in an interval of two years were evaluated retrospectively. From 116 patients (% 81,7) (therapy group); 67 patients (% 47,2) were using 10 mg/d alendronate, 25 patients (% 17,6) nasal calcitonin 200 ILJ/d and 24 patients (% 16,9) cyclic ethidronate therapy. 26 osteopenic patients (without antiresorptive therapy) were administered 500 mg/d elementary calcium and 0,25 mcg/d active vitamin D. Results: The mean values of T scores of L2-4 and the neck of femur in the first measurement of DEXA were as follow respectively: -2,48 ± 1,14 and -2,43 ± 1,1. Two years later, the mean values of DEXA measurements revealed for L2-4: -2,18 ± 1,14; for the neck of femur: -2,23 ± 1,1. The improvement in the T scores of the lumbary ver¬tebra and the neck of femur was 0,30 (% 12,1) and 1,19 (% 8,2) respectively (p < 0,0001). The improvement in T scores of the therapy group was: 0,38 (% 13,6) for lumbary vertebra, 0,23 (% 13,1) for the neck of femur. This was statistically significant when compared with the control group (p < 0,0001). Hovewer, among the drugs used, no statistically significant difference was observed. Conclusion: The efficacy of antiresorbtive drugs on the osteoporotic postmenopausal women were studied. At the end of the study period the improvement on bone density was found to be statistically significant, however no statistically significant change was observed among the drugs used.
Özet
Amaç: CTF İç Hastalıkları A.B.D. Geriatri polikliniğinde osteoporoz tanısı ile antirezorptif tedavi alan hastaların kemik mineral yoğunluğu değişikliklerini saptamak. Materyal-Metod: İki yıl arayla DEXA ölçümleri tekrarlanan 142 kadın hastanın verileri retrospektif olarak değerlendirildi. 116 vakalık tedavi grubunun (% 81,7) 67'si (% 47,2) alendronat 10 mg/gün, 25'i (% 17,6) nasal kalsitonin 200 İU/gün, 24'ü (% 16,9) siklik etidronat kullanırken; 26 vakalık antirezorptif-tedavi almayan osteopeni grubuna ise (% 18,3) sadece elementer kalsiyum 500 mg/gün ve aktif D vitamini 0,25 mcg/ gün replasmanı uygulanmıştı. Bulgular: 142 vakalık tüm grubun İlk DEXA.L2-4 T skorları ortalaması -2,48 ± 1,14; femur boynu ortalaması -2,43 ± 1,1; ikinci L2-4 ortalaması -2,18 ± 1,14; femur boynu ortalaması -2,23 ± 1,1 idi. T skorlarındaki düzel¬me lomberde ortalama 0,30 (% 12,1); femur boynunda ise ortalama 0,19 (% 8,2) olarak bulundu (p 0,05). Sonuç: Postmenopozal kadınlarda retrospektif olarak yaptığımız değerlendirmede osteoporoz tedavisinde kullanılan antirezorptif ilaçların lomber vertebra ve femur boynu kemik mineral yoğunluğu üzerinde anlamlı düzelme sağlamalarına rağmen birbirlerine üstünlükleri gözlenmedi.